Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus dexmedetomidine for emergence agitation after general anesthesia
ChiCTR2200055233Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and dexmedetomidine in Emergence agitation (EA) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Time from start of medication to resolution of agitation. Started Dec 2021; status: recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on ChiCTR2200055233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055233.